Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

Literature - Agarwal R, Rossignol P, Romero A et al., - The Lancet 2019. https://doi.org/10.1016/S0140-6736(19)32135-X

Introduction and methods

The principle mechanism underlying resistant hypertension may be excessive sodium retention [1]. This may explain why chronic kidney disease (CKD) is commonly associated with resistant hypertension. Several studies have suggested that patients with CKD showed an about three times higher prevalence of resistant hypertension than the general population of those without CKD [2,3]. Treatment-resistant hypertension is associated with elevated risk of CV events and end-stage kidney disease [2], underscoring the urgent need to treat this condition.

The PATHWAY-2 study demonstrated that add-on therapy with spironolactone was more effective at lowering blood pressure in resistant hypertension than bisoprolol, doxazosin or placebo [4], consistent with resistant hypertension seeming to be a sodium retaining state. Studies that evaluated spironolactone excluded patients with advanced CKD because of the risk of hyperkalemia.

Oral K+-binding agents are now available, such as patiromer. This is a sodium-free, non-absorbed, K+-binding polymer that can lower serum K+ in patients with hyperkalemia [5,6]. In heart failure patients, patiromer enabled spironolactone use and prevented hyperkalemia in those with eGFR <60 mL/min/1.73m² or a history of hyperkalemia that led to discontinuation of RAAS-blocking treatment. These data form the rationale for a randomized controlled trial to evaluate the use of patiromer as an adjunctive therapy to spironolactone in patients with resistant hypertension and CKD.

This phase 2 study, the AMBER trial [7], tested the safety and efficacy of patiromer administered once daily for 12 weeks to allow persistent use of spironolactone for the treatment of resistant hypertension in patients with CKD. 295 Patients from 62 outpatient centres were recruited, with eGFR between 25 and 45 mL/min/1.73m², serum K+ between 4.3 and 5.1 mmol/L and resistant hypertension. The study consisted of a run-in period of maximum 4 weeks, a 12 week double-blind treatment period (weekly visits in week 1-4 and then biweekly) and a follow-up visit two weeks after the week 12 visit or early termination. Adherence to spironolactone treatment was assessed in plasma at week 1, 4, 8 and 12.

Main results

• The primary endpoint, the difference between treatment groups in the proportion of patients remaining on spironolactone at week 12, was met. The patiromer group showed a higher proportion (126/147 [86%]) than the placebo group (98/148 [66%]), with a between-group difference of 19.5% (95%CI: 10.0-29.0, P<0.0001).
• More patients in the placebo group had serum K+ of ≥5.5 mmol/L than in the patiromer group (P<0.0001).
• The cumulative dose of spironolactone was 384.7 mg (95%CI: 140.4-629.0) higher in those on patiromer than in those on placebo (P=0.0021).
• The mean exposure time to spironolactone was 68.6 days (SE: 1.9) in the placebo group and 75.6 days (SE: 1.6) in the patiromer group, with a least squares mean between-group difference of 7.1 days (95%CI: 2.2-12.0, P=0.0045).
• In week 12, 51% of patients on placebo and 69% on patiromer (median daily dose: 9.8 g, IQR: 8.4-16.0) were receiving 50 mg of spironolactone.
• Combining the placebo and patiromer groups, 93% of patients had detectable concentrations of spironolactone at week 1, 96% at week 4, 91% at week 8 and 91% at week 12.
• There were few severe adverse events (patiromer: 2%, placebo: 1%) and serious adverse events (3% and 1%). Adverse events leading to study treatment discontinuation were more frequent in those on spironolactone plus placebo (14%) than plus patiromer (7%).

Conclusion

References

Find this article online at The Lancet